It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its first ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR ...

From the Holderness Family to Grandma C, social media personalities around Raleigh and Durham explain what will get lost if ...

Caidya, a clinical research organization (CRO) based in Raleigh, has raised $165 million in private equity to support its growth.

Seattle-based health data platform Truveta announced a $320 million round on Monday, while biotech startup Tune Therapeutics announced a $175 million round on Sunday. ALLtech helps growing tech ...